The content on this site is intended for healthcare professionals only
Dr Luis Raez reviews recent developments in tarlatamab for small cell lung cancer, highlighting findings from the DeLLphi-304 study, which demonstrated an overall survival benefit compared with standard chemotherapy in previously treated patients.
He discusses the potential role of tarlatamab in patients with brain metastases and emerging data on combining tarlatamab with immune checkpoint inhibitors as maintenance treatment.
He also explores findings from the DeLLphi-309 study investigating extended dosing intervals, which could reduce the frequency of clinic visits while maintaining treatment activity and improving convenience and quality of life for patients.
Finally, he considers the broader potential of emerging therapeutic targets to improve outcomes in small cell lung cancer.
Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC
Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC
Amivantamab plus chemotherapy extends overall survival in EGFR exon 20 insertion NSCLC
JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC
Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC
Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?
Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC
MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer
Durvalumab improves survival and delays progression in limited-stage small cell lung cancer
